Zingo™

June 7, 2008

Email this news item to a friend/colleague

In August 2007, the U.S. Food and Drug Administration (FDA) approved Zingo™ (lidocaine hydrochloride monohydrate) powder intradermal injection system to provide local analgesia prior to venipuncture or peripheral IV starts in children three to 18 years of age.

Anesiva the company behind Zingo™ have informed IVTEAM that this new product will be available from June 27th 2008.

Zingo™ delivers a powder form of lidocaine. Instead of using a needle to deliver the analgesic, Zingo™ uses compressed gas to accelerate the lidocaine particles into the skin. This provides analgesia in one to three minutes.

The Zingo™ website can be seen here and the Zingo™ package insert/instructions for use can be seen here.

For more information on Zingo™ send an e-mail to medinfo@anesiva.com

Readers may also benefit from reading about a study into needlefree lidocaine administration on our literature pages.

UPDATE - GE Capital extends loan deal with Anesiva, waives default.